ImmuCell Corporation Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ImmuCell Corporation (ICCC) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $2.24 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-08-14
- ImmuCell Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $841.14K.
- ImmuCell Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$18.39K.
- ImmuCell Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.70M, a 265.20% decline year-over-year.
- ImmuCell Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was $1.63M.
- ImmuCell Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $2.78M.
- ImmuCell Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$4.81M.
- ImmuCell Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$4.39M, a 235.80% decline from fiscal 2021.
- ImmuCell Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $3.24M, a 392.74% increase from fiscal 2020.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-06-30 | $2.24M 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $841.14K 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $2.78M 10-K · filed 2025-03-28 | |||
| 2024-09-30 | $2.83M 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $345.54K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$18.39K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$4.81M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | -$3.80M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | -$4.34M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$2.70M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$4.39M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$1.36M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $857.76K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $1.63M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $3.24M 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $3.55M 10-Q · filed 2022-11-21 | |||
| 2021-06-30 | $3.75M 10-Q/A · filed 2022-11-21 | |||
| 2021-03-31 | -$143.29K 10-Q/A · filed 2022-11-21 | |||
| 2020-12-31 | $656.64K 10-K · filed 2022-03-30 | |||
| 2020-09-30 | -$973.17K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $1.31M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $1.61M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $3.77M 10-K · filed 2021-03-30 | |||
| 2019-09-30 | -$166.49K 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$1.23M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |